This is a research study to find out if Qutenza 8% capsaicin topical system is safe and effective when treating subjects with lower back pain (LBP) that is caused by damage at or near the nerve's root in the lower back leg (lumbosacral radiculopathy) which is pain that can move all the way down the back of the leg. The pain may also start outside of the spinal cord, in the peripheral nerves and may also be felt all the way down the back of the leg (neuropathic LBP). Qutenza 8% capsaicin, the study drug, is currently FDA approved to treat nerve pain after a shingles outbreak in addition to a type of nerve pain in the feet associated with diabetes. In this study a maximum of four patches per visit (sized 14cm x 20 cm) will be used to deliver the Qutenza 8% capsaicin to the participants skin.
If a subject meets the qualifications for this study, in addition to their standard of care for their LBP, they can expect to have a total of 5 visits in a 12 month period. Each visit will require subjects to fill out several surveys and receive treatment patches for their LBP (your doctor will decide if participants will need to be retreated at each visit based on your symptoms). The study visits are estimated to take 90 minutes upwards to 120 minutes.

开始日期2025-03-13

申办/合作机构

Medical University of South Carolina

[+1]

NCT06444919

/ Recruiting临床4期IIT

Capsaicin in Digital Osteoarthritis Versus Control : a Randomized Study

The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component.
Participants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%).
Researchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)

开始日期2025-03-07

申办/合作机构

Centre Hospitalier Universitaire de Clermont Ferrand

[+1]

100 项与辣椒碱相关的临床结果

登录后查看更多信息

100 项与辣椒碱相关的转化医学

登录后查看更多信息

100 项与辣椒碱相关的专利（医药）

登录后查看更多信息

17,754

项与辣椒碱相关的文献（医药）

2025-09-01·TALANTA

Deep eutectic solvent-induced coacervation in micellar solution of alkyl polyglucoside surfactant: Supramolecular solvent formation and application in food analysis

Article

作者: Tobiszewski, Marek ; Yahya, Lutfi Andre ; Vakh, Christina ; Makoś-Chełstowska, Patrycja

The number of deep eutectic solvents were investigated to induce coacervation and cause phase separation in the micellar solution of the alkyl polyglucoside C₈-C₁₀. Three fatty acids were selected as hydrogen bond donors namely hexanoic acid, heptanoic acid, and octanoic acid, while quaternary ammonium salts and a monoterpenoid thymol were used as hydrogen bond acceptors to obtain deep eutectic solvents. The precursors of the deep eutectic solvents could be incorporated into the micelle structure of alkyl polyglucoside C₈-C₁₀ and modulate its properties, improving the interaction with the target compounds and promoting phase separation due to the increasing size of the micellar aggregates. The synergy of green surfactant and deep eutectic solvent has been demonstrated in the determination of capsaicinoids as secondary metabolites retaining the pungency of chili peppers and, thus, of spicy foods. Extraction recoveries were above 75 % for target analytes. The limits of detection were found to be 1.7 μg g ^-1 for capsaicin and dihydrocapsaicin. The relative recoveries were in the range of 76 -130 %. The research presented is the first example of synergy between alkyl polyglucoside and deep eutectic solvent. The proposed extraction system has the potential to be used in many other analytical tasks, especially in the analysis of solid and heterogeneous samples. Not only fatty acid-based deep eutectic solvents but other based on alcohols, monoterpenoids, etc. can also be used for coacervation. Thus, wide range of already studied deep eutectic solvents could be investigated for this purpose.

2025-06-01·AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL

Renal nerve afferents drive preferential renal sympathoexcitation in response to acute renal ischemia/reperfusion in rats

Article

作者: Gil, C D ; Campos, R R ; Knuepfer, M M ; Bergamaschi, C T ; Marreiros, A C ; Carvalhal, R S ; Nishi, E E ; Lantyer, R ; Santos, D D ; Milanez, M I O

Renal nerve activity is composed of afferent (sensory) and efferent (sympathetic) nerve activity. Ischemia/reperfusion (IR) of the kidney increases renal sympathetic nerve activity (rSNA) and depresses renal function. As the role of renal afferent fibers in acute renal IR is unclear, we tested the hypothesis that renal IR increases rSNA triggered by renal afferent nerves responding to acute ischemia. Two experimental series were performed in adult male Wistar rats. IR was induced by total obstruction of blood flow to the left kidney by clamping the renal artery for 60 min and reperfusion for 120 min. We recorded MAP, HR, rSNA, and splanchnic sympathetic vasomotor activity (sSNA) in 8 normal IR rats and 6 left kidney deafferented IR rats (IR ARD). Renal deafferentation was performed using capsaicin administration to the left renal nerve 2 weeks before the experiments. Blood samples were collected before ischemia and at the end of reperfusion for total and differential leukocyte counts. Renal ischemia significantly increased rSNA 23 % (20 min: 0,07 ± 0,04mVs P < 0.05) but not sSNA. The increase in rSNA was triggered by activation of renal afferent fibers, since IR significantly reduced rSNA in the IR ARD group maximal decrease in frequency 22 % (180 min: -62 ± 29Δspikes/s) and in amplitude 41 % (-0,29 ± 0, 12mVs, P < 0.05) and induced hypotension and bradycardia. However, no significant difference was observed between groups in blood leukocyte profile, but a significant reduction in renal IL-6 was found in IR ARD, suggesting a reduction in renal inflammation in deafferented IR rats. The results show that renal afferent nerves trigger a preferential increase in rSNA and inflammation in the kidney during acute IR.

2025-06-01·BIOCHEMICAL PHARMACOLOGY

Potential of capsaicin as a combinatorial agent to overcome chemoresistance and to improve outcomes of cancer therapy

Review

作者: Abbas, Mohamed ; Garhwal, Anushka ; Girisa, Sosmitha ; Kempson, Ivan ; Hegde, Mangala ; Vishwa, Ravichandran ; Abdulhammed, Ayman ; Alqahtani, Mohammed S ; Sethi, Gautam ; Sailo, Bethsebie Lalduhsaki ; Kunnumakkara, Ajaikumar B ; Mishra, Anamika

Capsaicin (CAPS), a bioactive alkaloid derived from chili peppers, has garnered significant interest for its potential role as a combinatorial and chemosensitizing agent in cancer therapy. Numerous preclinical studies have demonstrated that CAPS enhanced the efficacy of various anticancer agents by promoting apoptosis, modulating autophagy and inhibiting angiogenesis, tumor growth, and metastasis. Additionally, CAPS modulated critical regulators of chemoresistance, such as P-glycoprotein (P-gp), extracellular signal-regulated kinase (ERK), nuclear factor-kappa B (NF-κB) pathway, and signal transducer and activator of transcription 3 (STAT3) pathway, thereby contributing to the reversal of multidrug resistance (MDR). Moreover, when administered in combination with chemotherapeutic agents, CAPS has been shown to improve treatment efficacy at lower drug concentrations. Given its multitargeted mechanism of action, CAPS represents a promising adjunct to conventional cancer therapies. However, due to its lipophilic nature, the development of optimized formulation strategies is essential to enhance its bioavailability and ensure consistent therapeutic outcomes. In conclusion, CAPS holds significant potential as a combinatorial and chemosensitizing agent, helping to overcome chemoresistance and enhance treatment outcomes across various malignancies. These promising findings warrant further preclinical and clinical investigations.

项与辣椒碱相关的新闻（医药）

2025-03-21

·drugs

Not Much Works To Soothe Low Back Pain, Study Says

FRIDAY, March 21, 2025 -- There are a ton of suggestions out there for soothing an aching lower back -- acupuncture, heat, cannabinoids, muscle relaxants, TENS electrical pulses, dry cupping, opioids, massage and more. But not much actually eases back pain, including those suggestions, according to a new evidence review. Only painkillers like aspirin or ibuprofen -- non-steroidal anti-inflammatory drugs (NSAIDs) -- have been shown to be moderately effective in treating short-term lower back pain based on available medical evidence, researchers concluded. There’s also some evidence that five other treatments might help long-term low back pain, researchers said -- exercise , spinal manipulation, taping, antidepressants and warming creams containing ingredients like capsaicin . Overall, only 10% of treatments for low back pain had any medical evidence supporting their potential effectiveness, and even they didn’t work that great, concluded the review in the journal BMJ Evidence-Based Medicine . “Surprisingly, we found only around one in 10 was effective and most provided pain relief that was only marginally better than placebo – in other words, our review did not find reliable evidence of large effects for any of the included treatments,” Aidan Cashin , deputy director of the Center for Pain IMPACT at Neuroscience Research Australia, said in a news release. Non-surgical treatments are considered first-line care for back pain, Cashin said. Researchers performed the evidence review to see just how well these myriad therapies work. For the review, they analyzed findings from 301 clinical trials examining 56 treatments or treatment combinations for low back pain. Results showed that no sure-fire cures for back pain are currently available. Even ones with some evidence behind them can’t be counted on to work well for everyone. “We found for acute low back pain, NSAIDs may be effective. For chronic low back pain, exercise, spinal manipulation, taping, antidepressants and TRPV1 agonists (warming creams) may be effective,” Cashin said. “However, those effects were small.” Researchers also specifically highlighted five treatments that don’t work, based on the evidence. These included three for short-term low back pain – exercise, steroid injections and acetaminophen – and two for chronic back pain, antibiotics and anesthetics. For the rest of the treatments included in the research, there was simply not enough evidence to rule one way or the other, researchers concluded. More research is needed to prove whether or not these other back pain cures might have something to them. “We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams,” Cashin said. “Placebo-controlled studies are the gold standard for evaluating the effects of treatments, with a clear need to better understand which treatments work for people with low back pain,” he added. In the meantime, Cashin recommends that people with back pain talk to their medical team to understand the treatments available and find one that works best for them. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2025-02-24

·PRNewswire

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

TORONTO and AACHEN, Germany, Feb. 24, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain. Under the agreement, Searchlight Pharma ("Searchlight"), Apotex's specialty pharma division, will pursue marketing authorization for Qutenza and market and distribute Qutenza in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties. This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 branded, generic, and biosimilar pharmaceutical products. "Licensing the Canadian rights to Qutenza enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets," said Mark Nawacki, President of Searchlight. "This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care." "We have continuously developed Qutenza to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US," says Jan Adams, Chief Commercial Officer at Grünenthal. "Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain." Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities. About Qutenza ® In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit . Qutenza (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at . About Apotex and Searchlight Pharma Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets. Learn more about us at and at . About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group | Instagram: grunenthal Media contacts: Apotex: [email protected] Grünenthal Florian Dieckmann, Head Global Corporate Affairs +49 241 569-2555 [email protected] SOURCE Apotex Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准引进/卖出并购

2025-02-12

·医脉通

“吃辣”被写入高血压指南！怎么辣有讲究，这6类人千万别试

这些人群，该怎么对待辣椒？来源 | “医脉通健康关爱中心”微信公众号作者 | 苏暄 “湖南人不怕辣，四川人辣不怕，贵州人怕不辣！” 湖南的剁椒鱼头、四川的麻辣烫，到贵州的辣子鸡，很多人无辣不欢，没有辣椒，食物也好像没了灵魂。但你知道吗？2024年，“吃辣” 竟被写入了高血压防治指南，成了官方推荐！但是，对这种舌尖上的美味，有些人却得三思而后行。作为高频食物，辣椒到底是降压还是升压的，对健康有益还是有害？心血管病的患者，该怎么对待辣椒？🌶️ ▍辣椒到底降压还是升压？1-6 我国慢性病前瞻性研究项目的数据显示，常吃辣的人可以预防高血压。我国的研究者指出，辣椒等辛辣食物中的主要成分是辣椒素。辣椒素通过作用于特定的受体，促进血管内皮细胞产生一氧化氮，从而扩张血管，降低血压。这就解释了为啥加辣椒的食物能预防心血管疾病和代谢疾病。而且，2022年的一项综合分析还发现，喜欢吃辣的人患心血管疾病和癌症等疾病的死亡风险较低 5。女性中，每周吃辣超过3次的，比那些从不吃辣的，患高血压的风险低了12%。而且，每周吃辣的次数越多，血压就降得越明显3。在不喝酒的人中，每天吃辣的，比从不吃辣的，患高血压的风险低了28%3。喜欢吃辣的人，每天会比不喜欢吃辣的人少吃2.5克盐，这样一来，他们的收缩压和舒张压分别低6.6 mmHg和4.0mmHg2，所以，降低了患心血管疾病和癌症等疾病的死亡风险。 [1] 辣饮食对血压的影响 ▍心血管患者，该吃多少辣椒？1-6 综合高血压防治指南和医学建议，心血管病患者在吃辣椒时的具体建议如下：一. 适量食用，避免过量辣椒中的辣椒素对心血管健康有好处，比如促进血液循环和软化扩张血管。但吃太多辣椒，则会刺激神经，导致心跳加快、血压升高，加重心脏负担。症状较轻的心血管病患者：可以少量吃辣椒，但不要吃太多，以免刺激过度。辣椒中的成分对病情影响不大，但辣椒也可能导致心跳加快和心肌耗氧增加，所以要严格控制用量，并注意观察身体反应。二. 避免吃辣的心血管病人群 1. 症状较重的心血管病患者：如有严重的冠心病、心绞痛或有高血压并发症的人，最好不要吃辣椒。辣椒的刺激可能加重心脏负担，甚至引发过敏反应，如全身瘙痒、起红疹，严重时可能导致喉头水肿和呼吸困难，危及生命。 2. 对辣椒过敏的人：吃辣椒可能引发过敏反应，如皮肤瘙痒、呼吸困难，严重时可能危及生命。 3. 吃完辣椒胃难受的人：辣椒可能刺激胃部，增加回心血量，导致血压升高，对心血管健康不利。胃肠道疾病患者，吃辣椒会刺激胃黏膜，可能诱发或加重胃炎、胃溃疡、反流性食管炎等疾病。 TIP: 吃辣讲究个体化调整补充一下，心血管病患者是否能吃辣椒，要根据自身病情和医生建议决定。如果病情稳定，而且能吃辣，可少量尝试，如果病情较重或对辣椒敏感，就要避免吃辣。高血压患者对待辣椒也要谨慎。虽然辣饮食在某些情况下有好处，但不是说所有高血压患者都能随便吃辣。总之，心血管病患者在吃辣椒时要谨慎，要根据自身情况和医生建议决定是否吃辣，和吃辣的量和频率。如有疑问或吃辣后很不舒服，要及时咨询或就医。 4. 眼压高或青光眼患者虽然辣椒不会直接导致眼压升高，但过量食用可能刺激胃肠道，引起身体不适，间接影响眼压稳定。建议眼压高或青光眼患者控制辣椒摄入量，避免一次性食用过多。 5. 婴幼儿及儿童孩子的胃肠道功能尚未发育完全，辣椒可能刺激胃肠道，引起不舒服。建议儿童应避免食用辣食物，尤其是婴幼儿。 6. 吃中药、术后恢复期患者辣椒可能刺激伤口，延缓愈合，尤其是胃肠道手术后的患者。建议术后恢复期患者应避免吃辣，直至完全康复。食用辣椒素会影响中药疗效，服用中药的同时，应禁食辛辣食物。 ▍吃辣怎么做更健康？7 1. 煮熟再吃辣椒有干辣椒、鲜辣椒和腌辣椒等种类。专家建议，最好吃新鲜辣椒，营养更丰富。辣椒要煮熟再吃，生辣椒中的辣椒素，可能会刺激口腔和胃肠道黏膜，而加热后这种刺激会减少。 2. 搭配少油少盐的食物很多人喜欢油炸辣椒，但这样会更容易上火，特别是对那些容易上火的人不太适合，建议吃辣椒时尽量少放油和盐。 3. 根据体质选择吃辣每个人的体质不同，能承受的辣度也不同。手脚冰凉、容易贫血的人可以适当多吃辣椒。而阴虚火旺、经常便秘的人应少吃。 4. 根据气候情况吃辣在气候干燥的地方，要少吃辣椒，再吃辣椒会加重上火症状。相反，在潮湿多雨的地方可以吃点辣椒来祛湿御寒。参考文献 1. 中国高血压防治指南(2024年修订版） 2. LiQ,CuiY,JinR,etal.Enjoymentofspicyflavorenhances centralsalty-tasteperceptionandreducessaltintakeandblood pressure[J].Hypertension,2017,70(6):1291-1299. 3. WangH,ChenL,ShenD,etal.Associationbetweenfrequency of spicyfoodconsumptionandhypertension:across-sectional studyinZhejiangprovince,China[J].Nutr Metab (Lond),2021,18(1):70. 4. 祝之明,黎黎,刘道燕.辣椒素受体:从诺贝尔奖的温度感知机制到心血管疾病预防[J].中华心血管病杂志,2021,49(12):1187-1190. 5. LuoD,LiW,XieC,etal.Capsaicinattenuatesarterialcalcificationthrough promoting SIRT6-mediated deacetylation and degradationofHIF1α(hypoxic-induciblefactor-1alpha)[J].Hypertension,2022,79(5):906-917. 6. KaurM,VermaBR,ZhouL,etal.Associationofpepperintakewithall-causeandspecificcausemortality-asystematicreviewandmeta-analysis[J].AmJPrevCardiol,2022,9:100301. 7.这10种人不要吃辣，尤其是第一种，再喜欢也要忌口！新华社2018年01月25日责编｜米子阿泰封面图来源｜视觉中国国家开会，2025年加强对医务人员的关心关怀！一位医生的欢喜与担忧…… 首位中国医生！王拥军教授荣获国际卒中领域临床研究最高奖医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。 ☟戳这里，更有料！

100 项与辣椒碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00250	辣椒碱	M02AB01 N01BX04	DB06774

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病周围神经性疼痛	美国	Averitas Pharma, Inc.初创企业	2020-07-17
疱疹后神经痛	美国	Averitas Pharma, Inc.初创企业	2009-11-16
神经痛	中国	长春普华制药股份有限公司	2003-01-24
疼痛	中国	长春普华制药股份有限公司	2003-01-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
周围神经系统疾病	临床3期	法国	Grünenthal GmbH	2023-10-20
术后疼痛	临床3期	美国	Averitas Pharma, Inc.初创企业	2021-07-13
术后疼痛	临床3期	法国	Averitas Pharma, Inc.初创企业	2021-07-13
术后疼痛	临床3期	荷兰	Averitas Pharma, Inc.初创企业	2021-07-13
术后疼痛	临床3期	波兰	Averitas Pharma, Inc.初创企业	2021-07-13
术后疼痛	临床3期	西班牙	Averitas Pharma, Inc.初创企业	2021-07-13
术后疼痛	临床3期	英国	Averitas Pharma, Inc.初创企业	2021-07-13
乳腺癌	临床3期	法国	Grünenthal GmbH	2019-03-19
糖尿病周围神经病变	临床3期	比利时	Astellas Pharma, Inc.	2011-11-01
糖尿病周围神经病变	临床3期	捷克	Astellas Pharma, Inc.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2024	N/A	消化不良 \| 胃食管反流 \| 重度哮喘	-	CAPSAICIN (GERD (+))	製淵醖糧觸醖齋衊膚糧(艱蓋獵鹹醖廠選窪願蓋) = 夢膚夢餘積衊築顧艱鬱壓築廠窪顧壓鑰選鑰廠 (鏇顧簾鬱窪艱鏇壓鹹觸 )	-	2024-10-13
NCT03722849 (CTgov)	N/A	难治性慢性咳嗽	58	Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Chronic Cough Participant)	積築構醖選膚簾衊鑰蓋(膚鏇淵廠夢願廠鬱廠蓋) = 淵築鹽簾鑰構淵繭網淵鏇範膚構糧繭製艱繭網 (淵襯糧餘獵鏇衊築構淵, 0.60) 更多	-	2024-08-22
				Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Healthy Control Participant)	積築構醖選膚簾衊鑰蓋(膚鏇淵廠夢願廠鬱廠蓋) = 鹹觸鑰淵衊選鹹積鏇構鏇範膚構糧繭製艱繭網 (淵襯糧餘獵鏇衊築構淵, 0.47) 更多
ADA2024	N/A	糖尿病性神经病变	-	High Concentration Capsaicin Topical System (HCCTS)	鏇獵鹽選鏇簾鏇窪蓋衊(鹽衊蓋築鬱顧簾繭淵觸) = 鑰憲齋夢製醖選憲襯鑰夢鹹築獵積夢簾鏇積壓 (壓鑰鑰齋鏇範簾齋鏇願 ) 更多	-	2024-06-14
NCT04918069 (Pubmed)	临床3期	化疗引起的恶心和呕吐	160	Topical Capsaicin 0.075%	網糧鹽鹽積繭蓋簾簾鏇(糧顧願鹹觸構衊鏇齋鬱) = 憲鬱鑰窪鹽範積醖選顧膚齋鹹範獵範構衊構獵 (選範憲蓋憲糧蓋艱遞獵 ) 更多	积极	2024-06-01
				Placebo	積蓋蓋願鏇繭鏇膚構觸(製範壓願遞積觸憲顧窪) = 範顧鹹鹽繭築艱膚鏇構構鑰齋餘簾餘獵壓艱鹹 (鑰願製鬱繭構醖淵襯獵 ) 更多
NCT05298202 (CTgov)	临床4期	热衰竭	12	Hot environment+Capsaicin (Capsaicin Gel Application)	鹹醖願壓壓膚夢顧醖選(遞膚構窪糧衊選構壓齋) = 餘觸艱餘積範網鏇簾鹽艱艱選網顧膚鑰鹽鏇顧 (鹽製積顧衊鑰觸範鬱夢, 104.9) 更多	-	2024-03-15
				Control Gel (Hypoallergenic Gel Application)	鹹醖願壓壓膚夢顧醖選(遞膚構窪糧衊選構壓齋) = 積觸鏇廠顧淵衊醖艱糧艱艱選網顧膚鑰鹽鏇顧 (鹽製積顧衊鑰觸範鬱夢, 56.7) 更多
NCT04256733 (CTgov)	早期临床1期	咳嗽	19	Supra-threshold (Supra-threshold Capsaicin)	構醖鬱網顧淵淵窪淵鏇(鹽夢遞繭網積鬱構觸餘) = 淵積齋鏇簾壓築網簾淵廠鏇鹽遞夢積繭選淵鏇 (鹽選蓋構窪選餘築糧窪, 1.78) 更多	-	2024-03-04
				Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer (Sub-threshold Capsaicin)	構醖鬱網顧淵淵窪淵鏇(鹽夢遞繭網積鬱構觸餘) = 衊構齋構構齋簾範網襯廠鏇鹽遞夢積繭選淵鏇 (鹽選蓋構窪選餘築糧窪, 2.48) 更多
EBCC2022	N/A	辅助	35	Capsaicin patch 179 mg	壓餘範醖壓鬱醖繭憲鏇(糧繭繭網鑰積糧繭選繭) = 鑰顧壓衊鹹衊憲壓窪醖鬱齋憲選觸繭範獵簾糧 (艱齋衊蓋網範獵鹽顧鬱 ) 更多	-	2022-11-17
UEGW2022	N/A	吞咽障碍 TRPV1 agonist	51	Capsaicin 10Õ¼m	餘鹹艱壓鏇衊鑰範憲窪(構鹽齋鹹築鬱醖網鬱鹽) = 窪襯鏇鹹襯淵襯鏇鹹醖襯積醖壓齋觸觸構憲鬱 (膚範願積網網願網遞構 ) 更多	积极	2022-10-09
				Placebo	餘鹹艱壓鏇衊鑰範憲窪(構鹽齋鹹築鬱醖網鬱鹽) = 醖壓鏇繭艱選獵築壓製襯積醖壓齋觸觸構憲鬱 (膚範願積網網願網遞構 )
NCT03429049 (CTgov)	临床3期	膝关节炎	332	Placebo (Placebo)	壓鏇齋積獵鏇選餘壓糧(膚艱醖鹽膚齋範鬱製鬱) = 網糧顧鬱憲製醖廠簾淵艱鏇醖構窪憲蓋餘獵夢 (獵蓋淵鹽糧衊餘憲糧憲, 0.212) 更多	-	2022-04-08
				CNTX-4975-05 (CNTX-4975-05)	壓鏇齋積獵鏇選餘壓糧(膚艱醖鹽膚齋範鬱製鬱) = 蓋壓醖醖淵襯蓋選餘製艱鏇醖構窪憲蓋餘獵夢 (獵蓋淵鹽糧衊餘憲糧憲, 0.182) 更多
UEGW2021	N/A	疼痛	-	Capsaicin perfusion	鹽製餘構顧製蓋鏇鹽壓(鹹築範製遞選艱鑰廠鹽) = impaired recovery of the baseline impedance compared to saline-treated controls 憲鹽網壓醖蓋齋網遞齋 (膚鏇蓋願壓繭淵淵獵觸 )	-	2021-10-02